Monitoring the copy number status of HER2 in ctDNA is beneficial for the therapeutic effect of patients with HER2-positive gastric cancer and identifying treatment options for patients whose HER2 status changes to positive following recurrence. Here, ERBB2 is linked to gastric cancer.